Nicolas Folschweiller

Avenue Flemming 20
Waver, VLG 1300, Belgium

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications

Immunogenicity and safety of the live-attenuated tetravalent dengue vaccine (TAK-003) co-administered with recombinant 9-valent human papillomavirus vaccine.

Immunogenicity and safety of the live-attenuated tetravalent dengue vaccine (TAK-003) co-administered with recombinant 9-valent human papillomavirus vaccine.

Journal: Vaccine
Published: October 08, 2025

Estimated Efficacy of TAK-003 Against Asymptomatic Dengue Infection in Children and Adolescents Participating in the DEN-301 Trial in Asia Pacific and Latin America.

Estimated Efficacy of TAK-003 Against Asymptomatic Dengue Infection in Children and Adolescents Participating in the DEN-301 Trial in Asia Pacific and Latin America.

Journal: The Journal of infectious diseases
Published: September 17, 2024

Immunogenicity and safety of the live-attenuated tetravalent dengue vaccine (TAK-003) co-administered with recombinant 9-valent human papillomavirus vaccine.

Immunogenicity and safety of the live-attenuated tetravalent dengue vaccine (TAK-003) co-administered with recombinant 9-valent human papillomavirus vaccine.

Journal: Vaccine
Published: September 05, 2024

Early onset of protection of the TAK-003 dengue vaccine: Data from the DEN-301 clinical trial.

Early onset of protection of the TAK-003 dengue vaccine: Data from the DEN-301 clinical trial.

Journal: Vaccine
Published: June 07, 2024

Long term T cell response and safety of a tetravalent dengue vaccine in healthy children.

Long term T cell response and safety of a tetravalent dengue vaccine in healthy children.

Journal: NPJ vaccines
Published: March 15, 2024

Immunogenicity, Safety, and Efficacy of a Tetravalent Dengue Vaccine in Children and Adolescents: An Analysis by Age Group.

Immunogenicity, Safety, and Efficacy of a Tetravalent Dengue Vaccine in Children and Adolescents: An Analysis by Age Group.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: March 12, 2024

Role of the dengue vaccine TAK-003 in an outbreak response: Modeling the Sri Lanka experience.

Role of the dengue vaccine TAK-003 in an outbreak response: Modeling the Sri Lanka experience.

Journal: PLoS neglected tropical diseases
Published: August 03, 2023

Efficacy and Safety of a Tetravalent Dengue Vaccine (TAK-003) in Children With Prior Japanese Encephalitis or Yellow Fever Vaccination.

Efficacy and Safety of a Tetravalent Dengue Vaccine (TAK-003) in Children With Prior Japanese Encephalitis or Yellow Fever Vaccination.

Journal: The Journal of infectious diseases
Published: June 01, 2023

Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial.

Long-term efficacy and safety of a tetravalent dengue vaccine (TAK-003): 4·5-year results from a phase 3, randomised, double-blind, placebo-controlled trial.

Journal: The Lancet. Global health
Published: February 22, 2023

Effect of the Tetravalent Dengue Vaccine TAK-003 on Sequential Episodes of Symptomatic Dengue.

Effect of the Tetravalent Dengue Vaccine TAK-003 on Sequential Episodes of Symptomatic Dengue.

Journal: The American journal of tropical medicine and hygiene
Published: October 24, 2022

A randomized phase 3 trial of the immunogenicity and safety of coadministration of a live-attenuated tetravalent dengue vaccine (TAK-003) and an inactivated hepatitis a (HAV) virus vaccine in a dengue non-endemic country.

A randomized phase 3 trial of the immunogenicity and safety of coadministration of a live-attenuated tetravalent dengue vaccine (TAK-003) and an inactivated hepatitis a (HAV) virus vaccine in a dengue non-endemic country.

Journal: Vaccine
Published: September 05, 2022

Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults.

Bridging the immunogenicity of a tetravalent dengue vaccine (TAK-003) from children and adolescents to adults.

Journal: NPJ vaccines
Published: September 02, 2022
Showing 1-12 of 28

Last Updated: 09/26/2026